stronger and significantly more frequent than it has been shown previously. For the current clinical trial, 50 patients will be enrolled in Germany, Poland and Romania. The study aims to show ...
IC41 is a peptide vaccine currently in clinical development. It consists of five synthetic peptides from core, NS3 and NS4 proteins that are conserved across HCV genotypes 1 and 2, combined with the ...
Study will evaluate IC41 vaccine and nitazoxanide in treatment-naïve patients. Intercell and Romark Laboratories are teaming up to evaluate a combination of their respective HCV vaccine IC41 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results